NAUSEA MEDICINE MARKET ANALYSIS

Market News

• In January 2023, Helsinn Group, a global biopharma company, and Immedica Pharma AB, a pharmaceutical company focused on the commercialization of rare and specialty care products, have announced an exclusive long-term license and distribution agreement for the commercialization of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets: AKYNZEO (Netupitant-Palonosetron fixed combination) and AKYNZEO (Palonosetron).
• In March 2021, Starton Therapeutics Inc., a U.S.-based privately held clinical-stage biopharmaceutical company, and Haisco Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, announced that they have entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ, a once-weekly transdermal olanzapine delivery system in development for nausea and vomiting, in Mainland China.
• In January 2022, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the acquisition of SANCUSO (granisetron transdermal patch), an U.S. FDA-approved oncology-supportive care medicine, from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company focused on discovering and delivering novel medicines. SANCUSO is the first and only prescription patch authorized by the US FDA to reduce nausea and vomiting in patients undergoing specific forms of chemotherapy.

New product launches

• Akynzeo IV (fosnetupitant/palonosetron) is a fixed-dose combination injection that is used to prevent chemotherapy-induced nausea and vomiting (CINV). It was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is available in the United States.
• Barhemsys (amisulpride) is an intravenous solution that is used to treat and prevent postoperative nausea and vomiting (PONV). It was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is available in the U.S.
• In September 2022, Heron Therapeutics, a commercial-stage biotechnology company announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.